company background image
4503

Astellas Pharma TSE:4503 Stock Report

Last Price

JP¥2.05k

Market Cap

JP¥3.7t

7D

2.3%

1Y

14.2%

Updated

08 Aug, 2022

Data

Company Financials +
4503 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance2/6
Financial Health5/6
Dividends5/6

4503 Stock Overview

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide.

Astellas Pharma Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Astellas Pharma
Historical stock prices
Current Share PriceJP¥2,052.00
52 Week HighJP¥2,205.00
52 Week LowJP¥1,736.00
Beta0.56
1 Month Change-3.30%
3 Month Change4.91%
1 Year Change14.19%
3 Year Change43.20%
5 Year Change48.21%
Change since IPO248.98%

Recent News & Updates

Shareholder Returns

4503JP PharmaceuticalsJP Market
7D2.3%4.1%1.2%
1Y14.2%5.2%-0.3%

Return vs Industry: 4503 exceeded the JP Pharmaceuticals industry which returned 6% over the past year.

Return vs Market: 4503 exceeded the JP Market which returned -0.1% over the past year.

Price Volatility

Is 4503's price volatile compared to industry and market?
4503 volatility
4503 Average Weekly Movement3.6%
Pharmaceuticals Industry Average Movement4.1%
Market Average Movement4.0%
10% most volatile stocks in JP Market8.1%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4503 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 4503's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
192314,522Kenji Yasukawahttps://www.astellas.com

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent.

Astellas Pharma Inc. Fundamentals Summary

How do Astellas Pharma's earnings and revenue compare to its market cap?
4503 fundamental statistics
Market CapJP¥3.75t
Earnings (TTM)JP¥118.21b
Revenue (TTM)JP¥1.35t

31.7x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4503 income statement (TTM)
RevenueJP¥1.35t
Cost of RevenueJP¥279.65b
Gross ProfitJP¥1.07t
Other ExpensesJP¥953.95b
EarningsJP¥118.21b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 31, 2022

Earnings per share (EPS)64.70
Gross Margin79.31%
Net Profit Margin8.74%
Debt/Equity Ratio0.3%

How did 4503 perform over the long term?

See historical performance and comparison

Dividends

2.9%

Current Dividend Yield

78%

Payout Ratio

Does 4503 pay a reliable dividends?

See 4503 dividend history and benchmarks
When do you need to buy 4503 by to receive an upcoming dividend?
Astellas Pharma dividend dates
Ex Dividend DateSep 29 2022
Dividend Pay DateDec 01 2022
Days until Ex dividend51 days
Days until Dividend pay date114 days

Does 4503 pay a reliable dividends?

See 4503 dividend history and benchmarks